GameStop Corp. vs Nuwellis Inc — how do they compare? GameStop Corp. trades at $26.56 (market cap $12.75B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: GameStop Corp. is far larger — about 5795.5× Nuwellis Inc's market cap, and GameStop Corp. is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and Nuwellis Inc for 26 Days on average.
| GME | NUWE | |
|---|---|---|
Market Cap | $12.75B | $2.20M |
Volume | 13,026,993 | 121,544 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.53 | $146.65 |
52-Week Low | $17.87 | $0.68 |
Typical Hold Time | 62 Days | 26 Days |
Enterprise Value | $12.03B | -$1.52M |
Signals from Pluang's Aura AI — not financial advice
GME trades at $26.56, up 8.06% over 24 hours, with a bullish technical signal supported by moving averages. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company reported net income of $131.3 million in 2025, a significant turnaround from prior losses, while revenue declined to $3.82 billion. Strong insider buying by CEO Ryan Cohen and directors has fueled positive sentiment, though analyst consensus remains cautious with a majority hold rating.
The outlook for GME hinges on execution of its strategic pivot to high-margin collectibles and leveraging its $4.77 billion cash position. Key risks include revenue volatility, competitive pressures, and dependence on insider confidence. Upside potential exists if earnings growth sustains, but investors face uncertainty from inconsistent profitability and high valuation multiples relative to historical performance.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →